Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by La Jolla Pharmaceutical Company

La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022
From La Jolla Pharmaceutical Company
Via Business Wire
Innoviva to Acquire La Jolla Pharmaceutical Company
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers INVA LJPC
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate Progress
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC
La Jolla Pharmaceutical Company Announces Share Repurchase Plan
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate Progress
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC
Tony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical Company
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
From La Jolla Pharmaceutical Company
Via Business Wire
Tickers LJPC
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.